Johnson Pharmacare Limited

Financial Results Summary

Statement of Profit and Loss (₹ in Lakhs)

  • Total Income: ₹158.10 for FY26 (consisting entirely of Other Income)
  • Total Expenses: ₹4,304.49 for FY26
  • Loss before exceptional items and tax: ₹(4,146.39) for FY26
  • Exceptional Items: ₹1,427.00 (Loans & Advances Write-Off)
  • Loss before tax: ₹(5,573.39) for FY26
  • Tax expense: ₹0 (No current or deferred tax provision)
  • Net Loss for the period: ₹(5,573.39) for FY26
  • Earnings per share (Basic/Diluted): ₹(1.01) for FY26

Balance Sheet Position (as at March 31, 2026, ₹ in Lakhs)

  • Total Assets: ₹2,203.11 (down from ₹5,792.59 in FY25)
  • Non-Current Assets: ₹1,972.50 (primarily Investments)
  • Current Assets: ₹230.61 (including Cash & Cash Equivalents of ₹8.00)
  • Equity Share Capital: ₹5,500.00 (unchanged)
  • Other Equity: ₹(5,456.48) (deteriorated from positive ₹116.91 in FY25)
  • Total Equity: ₹43.52 (down from ₹5,616.91 in FY25)
  • Non-Current Liabilities: ₹2,140.19 (Borrowings)
  • Current Liabilities: ₹19.41

Cash Flow Statement (FY26, ₹ in Lakhs)

  • Net cash from operating activities: ₹(5,756.74)
  • Net cash used in investing activities: ₹3,683.66
  • Net cash used in financing activities: ₹2,079.65
  • Net increase in cash: ₹6.57
  • Cash at beginning: ₹1.43
  • Cash at end: ₹8.00

Audit Qualifications and Key Findings

Independent Auditor's Report (VRSK & Associates)

  • Opinion: Disclaimer of opinion due to non-provision of interest on loans and non-compliance with Indian Accounting Standards (Ind AS)
  • Key Audit Matters:
  • Inter-corporate loans of ₹2,140.04 lakhs with undefined terms (repayment schedule, interest rate, securities)
  • Fair valuation of unquoted investments worth ₹1,972.50 lakhs requiring significant judgment
  • Non-compliance noted: Financial statements not prepared in compliance with Ind AS as prescribed

Annexure A Findings

  • Loans & Investments: Company invested in shares of group companies exceeding limits prescribed under section 186 of Companies Act, 2013
  • Statutory Dues: Pending tax demands totaling ₹351.81 lakhs across multiple assessment years (AY 1996-97: ₹233.02L, AY 2015-16: ₹108.95L, etc.)
  • Cash Losses: Incurred cash losses of ₹11,123.52 lakhs in current year and ₹58.38 lakhs in previous year
  • RBI Registration: Company required to be registered under section 45-IA of RBI Act, 1934 but not registered
  • Going Concern: Company not capable of meeting liabilities falling due within one year from balance sheet date

Internal Financial Controls

Auditors expressed qualified opinion on adequacy and operating effectiveness of internal financial controls, identifying deficiencies that could impact reliability of financial reporting process.

Board and Audit Committee Approval

  • Financial results approved by Board of Directors at meeting held on May 27, 2026 (7:15 PM to 7:45 PM)
  • Results reviewed by Audit Committee chaired by Parul Agrawal
  • Statutory Auditor: VRSK & Associates (FRN: 011199N), Partner: CA Vineet Gupta (M.No. 089823)

Additional Notes

  • Previous year figures regrouped for comparability
  • Company primarily engaged in investment activities with income mainly from interest
  • No branch offices, subsidiaries, joint ventures or associate companies
  • No fraud reported or detected during the year
  • No dividend declared or proposed during the year